Targeted inhibition of coagulation: oral agents show promise in phase III trials.
Bauer
K A
KA
VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02130, USA. kbauer@bidmc.harvard.edu
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects; D017326:Clinical Trials, Phase III as Topic; D016503:Drug Delivery Systems; D006801:Humans
D000925:Anticoagulants